Literature DB >> 18058141

Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit.

T Saito1, S Yoshioka, Y Iinuma, S Takakura, N Fujihara, T Ichinohe, T Ishikawa, T Uchiyama, S Ichiyama.   

Abstract

The emergence of fluoroquinolone-resistant gram-negative organisms has been demonstrated in patients given fluoroquinolone prophylaxis. To prevent increases in resistant bacteria, we restricted prophylactic use of fluoroquinolones. The spectrum and susceptibility patterns of isolates causing bloodstream infection (BSI) were assessed in patients receiving chemotherapy during periods of routine prophylaxis (period A: October 2001 to May 2003) and restricted prophylaxis (period B: June 2003 to January 2005). The total number of patients receiving chemotherapy was 442 during period A and 365 during period B. No significant differences were seen between periods with respect to patient characteristics. BSI was identified in 42 patients (44 episodes) during period A and 69 patients (74 episodes) during period B. Incidence of BSI increased significantly from 10.0% (44/442) during period A to 20.3% (74/365) during period B (P < 0.0001). Rate of Enterobacteriaceae BSI increased significantly, from 2.0% (9/442) during period A to 8.2% (30/365) during period B (P < 0.0001). For all BSI episodes, the proportion of BSI with gram-positive cocci decreased from 63.6% (28/44) during period A to 44.6% (33/74) during period B (P = 0.045), while the proportion of BSI with Enterobacteriaceae increased from 20.5% (9/44) to 40.5% (30/74) (P < 0.0001). The proportion of fluoroquinolone-resistant Enterobacteriaceae BSI for all Enterobacteriaceae BSI decreased from 75% (9/12) during period A to 17% (5/30) during period B (P = 0.0078). Restriction of fluoroquinolone prophylaxis affects the etiology of BSI and reduces the proportion of drug-resistant organisms.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18058141     DOI: 10.1007/s10096-007-0428-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  21 in total

1.  2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer.

Authors:  Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young
Journal:  Clin Infect Dis       Date:  2002-02-13       Impact factor: 9.079

2.  Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Leonard Leibovici
Journal:  Ann Intern Med       Date:  2005-06-21       Impact factor: 25.391

3.  Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer--is it justified?

Authors:  M Murphy; A E Brown; K A Sepkowitz; E M Bernard; T E Kiehn; D Armstrong
Journal:  Clin Infect Dis       Date:  1997-08       Impact factor: 9.079

4.  Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.

Authors:  Michael Cullen; Neil Steven; Lucinda Billingham; Claire Gaunt; Mark Hastings; Peter Simmonds; Nicholas Stuart; Daniel Rea; Mark Bower; Indrajit Fernando; Robert Huddart; Simon Gollins; Andrew Stanley
Journal:  N Engl J Med       Date:  2005-09-08       Impact factor: 91.245

Review 5.  Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria.

Authors:  S H Zinner
Journal:  Clin Infect Dis       Date:  1999-09       Impact factor: 9.079

6.  Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia.

Authors:  A Cometta; T Calandra; J Bille; M P Glauser
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

Review 7.  Prevention of infection in neutropenic cancer patients.

Authors:  J Klastersky
Journal:  Curr Opin Oncol       Date:  1996-07       Impact factor: 3.645

8.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients.

Authors:  J Klastersky; M Paesmans; E B Rubenstein; M Boyer; L Elting; R Feld; J Gallagher; J Herrstedt; B Rapoport; K Rolston; J Talcott
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

Review 9.  Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials.

Authors:  M D van de Wetering; M A de Witte; L C M Kremer; M Offringa; R J P M Scholten; H N Caron
Journal:  Eur J Cancer       Date:  2005-07       Impact factor: 9.162

10.  Fever and neutropenia clinical practice guidelines.

Authors:  Alison G Freifeld; Lindsey Robert Baden; Arthur E Brown; Linda S Elting; Michael Gelfand; John N Greene; James I Ito; Earl King; Guido Marcucci; Jose G Montoya; Ashley Morris; Gary Noskin; Ken Rolston; Anne F Schott; Brahm Segal
Journal:  J Natl Compr Canc Netw       Date:  2004-09       Impact factor: 11.908

View more
  11 in total

1.  Hospital-Level Variability in Broad-Spectrum Antibiotic Use for Children With Acute Leukemia Undergoing Hematopoietic Cell Transplantation.

Authors:  Caitlin W Elgarten; Staci D Arnold; Yimei Li; Yuan-Shung V Huang; Marcie L Riches; Jeffrey S Gerber; Richard Aplenc; Wael Saber; Brian T Fisher
Journal:  Infect Control Hosp Epidemiol       Date:  2018-05-08       Impact factor: 3.254

Review 2.  Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance.

Authors:  E Montassier; E Batard; T Gastinne; G Potel; M F de La Cochetière
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-25       Impact factor: 3.267

Review 3.  The prevention and management of infections due to multidrug resistant organisms in haematology patients.

Authors:  Jason A Trubiano; Leon J Worth; Karin A Thursky; Monica A Slavin
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

4.  Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning.

Authors:  Chisaki Mizumoto; Junya Kanda; Tatsuo Ichinohe; Takayuki Ishikawa; Masashi Matsui; Norimitsu Kadowaki; Tadakazu Kondo; Kazunori Imada; Masakatsu Hishizawa; Hiroshi Kawabata; Momoko Nishikori; Kouhei Yamashita; Akifumi Takaori-Kondo; Toshiyuki Hori; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2009-04-11       Impact factor: 2.490

5.  Ambulatory consolidation chemotherapy for acute myeloid leukemia with antibacterial prophylaxis is associated with frequent bacteremia and the emergence of fluoroquinolone resistant E. Coli.

Authors:  Lalit Saini; Coleman Rostein; Eshetu G Atenafu; Joseph M Brandwein
Journal:  BMC Infect Dis       Date:  2013-06-22       Impact factor: 3.090

6.  Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO).

Authors:  Annika Y Classen; Larissa Henze; Marie von Lilienfeld-Toal; Georg Maschmeyer; Michael Sandherr; Luisa Durán Graeff; Nael Alakel; Maximilian Christopeit; Stefan W Krause; Karin Mayer; Silke Neumann; Oliver A Cornely; Olaf Penack; Florian Weißinger; Hans-Heinrich Wolf; Jörg Janne Vehreschild
Journal:  Ann Hematol       Date:  2021-04-13       Impact factor: 3.673

7.  Prophylaxis with levofloxacin: impact on bacterial susceptibility and epidemiology in a hematopoietic stem cell transplant unit.

Authors:  Livia Amaral Alonso Lopes; Izelândia Veroneze; Célia Inês Burgardt; Christiane Johnscher Niebel Stier
Journal:  Rev Bras Hematol Hemoter       Date:  2014

8.  Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis.

Authors:  Yong Chong; Shinji Shimoda; Hiroko Yakushiji; Yoshikiyo Ito; Takatoshi Aoki; Toshihiro Miyamoto; Tomohiko Kamimura; Nobuyuki Shimono; Koichi Akashi
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

9.  Incomplete recovery of the fecal flora of hematological patients with neutropenia and repeated fluoroquinolone prophylaxis.

Authors:  Yong Chong; Shinji Shimoda; Noriko Miyake; Takatoshi Aoki; Yoshikiyo Ito; Tomohiko Kamimura; Nobuyuki Shimono
Journal:  Infect Drug Resist       Date:  2017-06-27       Impact factor: 4.003

Review 10.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer
Journal:  Ann Hematol       Date:  2017-08-30       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.